Do Urate Targets Influence CV Risk?
-
By
January 30, 2026
-
3 min
-
1
27% of gout patients reached serum urate target < 6 mg/dL in 12 months.
-
2
Achieving this target lowered MACE risk by 9%.
-
3
Serum urate levels under 5 mg/dL reduced MACE risk by 23%.
-
4
Allopurinol was prescribed to nearly all patients.
-
5
Study involved 109,504 adults, mean age
-
6
Follow-up averaged 3.5 years, with a 14% MACE occurrence.
-
7
Potential bias from observational design noted.
-
8
Treat-to-target approach linked with fewer gout flares.
-
A recent study involving over 109,000 adults with newly diagnosed gout found that only 27% achieved the recommended serum urate target of less than 6 mg/dL within 12 months of starting urate-lowering treatment (ULT). Achieving this target was linked to a 9% reduction in the relative risk of major adverse cardiovascular events (MACE), particularly in patients with high cardiovascular risk. Notably, achieving even lower urate levels under 5 mg/dL correlated with a 23% risk reduction for MACE, highlighting the significance of targeted treatment in managing gout and its cardiovascular complications.
-
1
27% of gout patients reached serum urate target < 6 mg/dL in 12 months.
-
2
Achieving this target lowered MACE risk by 9%.
-
3
Serum urate levels under 5 mg/dL reduced MACE risk by 23%.
-
4
Allopurinol was prescribed to nearly all patients.
-
5
Study involved 109,504 adults, mean age
-
6
Follow-up averaged 3.5 years, with a 14% MACE occurrence.
-
7
Potential bias from observational design noted.
-
8
Treat-to-target approach linked with fewer gout flares.
Listen Tab content
